D.E. Shaw & Co
ARLZ

D.E. Shaw & Co’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

D.E. Shaw & Co’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-105,410
Closed -$150K – 3989
2017
Q4 		$150K Buy
105,410
+82,898
+368% +$136K ﹤0.01% 3462
2017
Q3 		$52K Buy
22,512
+6,160
+38% +$8.24K ﹤0.01% 3405
2017
Q2 		$22K Buy
+16,352
New +$23.6K ﹤0.01% 3326
2017
Q1 		– Sell
-37,621
Closed -$166K – 3821
2016
Q4 		$166K Sell
37,621
-283,185
-88% -$1.34M ﹤0.01% 3294
2016
Q3 		$1.56M Buy
320,806
+179,345
+127% +$818K ﹤0.01% 2102
2016
Q2 		$467K Sell
141,461
-233,866
-62% -$883K ﹤0.01% 2822
2016
Q1 		$1.33M Buy
+375,327
New +$1.93M ﹤0.01% 2167

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return

D.E. Shaw & Co's ARLZ Position: Q1 2018 in Review

D.E. Shaw & Co sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2018, closing a stake of 105,410 shares — an estimated $150K sold.

D.E. Shaw & Co first reported a position in ARLZ in Q1 2016 and held it in 7 quarters. The position peaked at $1.56M in Q3 2016. 56 funds tracked by Wall St. Rank hold ARLZ as of Q1 2018.

  • D.E. Shaw & Co reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 105,410 Aralez Pharmaceuticals Inc. shares in Q1 2018, an estimated $150K.
  • D.E. Shaw & Co first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 7 quarters.
  • D.E. Shaw & Co's Aralez Pharmaceuticals Inc. position peaked at $1.56M in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.